Business Context and Reporting Period
Company: Quantum-Si Inc (QSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Quantum-Si is a life sciences company focused on proteomics research, developing a proprietary single-molecule detection platform for Next-Gen Protein Sequencing (NGPS). The company operates as a single reportable segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Total Revenue | $591 | $1,433 | - |
| Gross Profit | $351 | $837 | - |
| Gross Margin | 59.4% | 58.4% | - |
| Net Loss | $(28,836) | $(48,025) | - |
| Loss Per Share (Basic & Diluted) | $(0.16) | $(0.26) | - |
| Cash & Cash Equivalents | - | - | $22,188 |
| Marketable Securities | - | - | $192,023 |
| Total Liquidity | - | - | $214,211 |
| Accumulated Deficit | - | - | $(644,666) |
Material Changes vs. Prior Period
- Revenue: Total revenue decreased 5.0% to $0.6 million for the three months ended June 30, 2025, compared to the prior year, driven by longer capital sales cycles and NIH budget constraints. However, for the six-month period, revenue increased 32.8% to $1.4 million, buoyed by strong Q1 2025 performance.
- Operating Expenses: Operating expenses increased 13.7% for the quarter and 11.2% for the six months. This was primarily due to a one-time Legal settlement expense of $3.4 million (net of insurance) related to the Delaware Stockholder Litigation.
- Net Loss: Net loss increased 24.8% for the quarter and 12.8% for the six months compared to the prior year periods, reflecting the legal settlement charge and increased R&D spend.
- Warrant Liabilities: The company recognized a $1.0 million loss on the change in fair value of warrant liabilities for the quarter, compared to a $0.5 million gain in the prior year quarter. For the six months, a $2.4 million gain was recognized.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($214.2 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring negative operating cash flows until revenue scales.
- Product Roadmap: The company launched the Platinum Pro benchtop sequencer in January 2025 with first shipments in March 2025. The next-generation platform, Proteus, is estimated to launch in the second half of 2026.
- Recent Financing:
- January 2025: Completed a registered direct offering raising $50.0 million gross ($46.8 million net).
- July 2025 (Subsequent Event): Completed a registered direct offering raising approximately $50.0 million gross ($46.9 million net) at $1.67 per share, including pre-funded warrants.
- Legal Contingencies:
- Delaware Stockholder Litigation: A preliminary settlement was reached in July 2025. The company recorded an $8.0 million liability and a $4.6 million insurance receivable, resulting in a net expense of $3.4 million. Final court approval is pending.
- Contract Manufacturer Dispute: Ongoing litigation with a former contract manufacturer; the outcome is not estimable.
- Risks: Risks include the inability to raise additional capital, delays in product commercialization, reliance on government funding (NIH), and potential impacts from global economic conditions and tariffs.
Investor Verification Checklist
- Legal Settlement Finality: Verify the status of the Delaware Stockholder Litigation settlement and the likelihood of final court approval to confirm the $3.4 million net expense.
- Revenue Sustainability: Assess the impact of NIH budget cuts on future capital sales cycles and the ability to maintain the 32.8% year-over-year revenue growth seen in the six-month period.
- Cash Burn Rate: Monitor the net cash used in operating activities ($46.4 million for six months) against the $214.2 million liquidity position to validate the 12-month runway.
- Warrant Liability Volatility: Review the fair value assumptions for Public and Private Warrants, as fluctuations in the stock price significantly impact non-cash earnings.
- Subsequent Financing Terms: Review the terms of the July 2025 registered direct offering, specifically the dilution impact of the pre-funded warrants issued at $0.0001 exercise price.